Comparative assessment of the anxiolytic-like activities of honokiol and derivatives

Hisashi Kuribara, Eiko Kishi, Masayuki Kimura, Susan E Weintraub, Yuji Maruyama

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Honokiol has previously been shown to be an effective anxiolytic-like agent in mice when administered for 7 days at 0.2 mg/kg/day prior to evaluation in an elevated plus-maze, while 20 mg/kg is required for efficacy as a single oral dose. The aim of this study was to find analogs of honokiol that are more effective for acute administration. Among the eight analogs evaluated, one partially reduced derivative of honokiol [3′-(2-propenyl)-5-propyl-(1,1′-biphenyl)-2,4′-diol] exhibited significant anxiolytic-like activity at 0.04 mg/kg. Following oral administration of 1 mg/kg of this analog, anxiolytic-like activity was clearly evident at 1 h, peaked at 3 h, and remained significant for longer than 4 h after treatment. Combined administration of the derivative with diazepam led to enhanced anxiolytic-like efficacy. Moreover, as with diazepam, the anxiolytic-like effect of the analog was reduced by flumazenil. In contrast, bicuculline, a GABAA antagonist, had no effect on the activity of the derivative. Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABAA-benzodiazepine receptor complex.

Original languageEnglish (US)
Pages (from-to)597-601
Number of pages5
JournalPharmacology Biochemistry and Behavior
Volume67
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Anti-Anxiety Agents
Derivatives
GABA-A Receptors
Diazepam
GABA-A Receptor Antagonists
Flumazenil
Bicuculline
Benzodiazepines
Oral Administration
honokiol

Keywords

  • Anxiolytic-like activity
  • Elevated plus-maze
  • Honokiol
  • Honokiol analogs
  • Hydrogenated honokiols

ASJC Scopus subject areas

  • Biochemistry
  • Behavioral Neuroscience
  • Pharmacology

Cite this

Comparative assessment of the anxiolytic-like activities of honokiol and derivatives. / Kuribara, Hisashi; Kishi, Eiko; Kimura, Masayuki; Weintraub, Susan E; Maruyama, Yuji.

In: Pharmacology Biochemistry and Behavior, Vol. 67, No. 3, 2000, p. 597-601.

Research output: Contribution to journalArticle

Kuribara, Hisashi ; Kishi, Eiko ; Kimura, Masayuki ; Weintraub, Susan E ; Maruyama, Yuji. / Comparative assessment of the anxiolytic-like activities of honokiol and derivatives. In: Pharmacology Biochemistry and Behavior. 2000 ; Vol. 67, No. 3. pp. 597-601.
@article{657f91ad62354adcb615b2634f0495de,
title = "Comparative assessment of the anxiolytic-like activities of honokiol and derivatives",
abstract = "Honokiol has previously been shown to be an effective anxiolytic-like agent in mice when administered for 7 days at 0.2 mg/kg/day prior to evaluation in an elevated plus-maze, while 20 mg/kg is required for efficacy as a single oral dose. The aim of this study was to find analogs of honokiol that are more effective for acute administration. Among the eight analogs evaluated, one partially reduced derivative of honokiol [3′-(2-propenyl)-5-propyl-(1,1′-biphenyl)-2,4′-diol] exhibited significant anxiolytic-like activity at 0.04 mg/kg. Following oral administration of 1 mg/kg of this analog, anxiolytic-like activity was clearly evident at 1 h, peaked at 3 h, and remained significant for longer than 4 h after treatment. Combined administration of the derivative with diazepam led to enhanced anxiolytic-like efficacy. Moreover, as with diazepam, the anxiolytic-like effect of the analog was reduced by flumazenil. In contrast, bicuculline, a GABAA antagonist, had no effect on the activity of the derivative. Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABAA-benzodiazepine receptor complex.",
keywords = "Anxiolytic-like activity, Elevated plus-maze, Honokiol, Honokiol analogs, Hydrogenated honokiols",
author = "Hisashi Kuribara and Eiko Kishi and Masayuki Kimura and Weintraub, {Susan E} and Yuji Maruyama",
year = "2000",
doi = "10.1016/S0091-3057(00)00401-9",
language = "English (US)",
volume = "67",
pages = "597--601",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Comparative assessment of the anxiolytic-like activities of honokiol and derivatives

AU - Kuribara, Hisashi

AU - Kishi, Eiko

AU - Kimura, Masayuki

AU - Weintraub, Susan E

AU - Maruyama, Yuji

PY - 2000

Y1 - 2000

N2 - Honokiol has previously been shown to be an effective anxiolytic-like agent in mice when administered for 7 days at 0.2 mg/kg/day prior to evaluation in an elevated plus-maze, while 20 mg/kg is required for efficacy as a single oral dose. The aim of this study was to find analogs of honokiol that are more effective for acute administration. Among the eight analogs evaluated, one partially reduced derivative of honokiol [3′-(2-propenyl)-5-propyl-(1,1′-biphenyl)-2,4′-diol] exhibited significant anxiolytic-like activity at 0.04 mg/kg. Following oral administration of 1 mg/kg of this analog, anxiolytic-like activity was clearly evident at 1 h, peaked at 3 h, and remained significant for longer than 4 h after treatment. Combined administration of the derivative with diazepam led to enhanced anxiolytic-like efficacy. Moreover, as with diazepam, the anxiolytic-like effect of the analog was reduced by flumazenil. In contrast, bicuculline, a GABAA antagonist, had no effect on the activity of the derivative. Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABAA-benzodiazepine receptor complex.

AB - Honokiol has previously been shown to be an effective anxiolytic-like agent in mice when administered for 7 days at 0.2 mg/kg/day prior to evaluation in an elevated plus-maze, while 20 mg/kg is required for efficacy as a single oral dose. The aim of this study was to find analogs of honokiol that are more effective for acute administration. Among the eight analogs evaluated, one partially reduced derivative of honokiol [3′-(2-propenyl)-5-propyl-(1,1′-biphenyl)-2,4′-diol] exhibited significant anxiolytic-like activity at 0.04 mg/kg. Following oral administration of 1 mg/kg of this analog, anxiolytic-like activity was clearly evident at 1 h, peaked at 3 h, and remained significant for longer than 4 h after treatment. Combined administration of the derivative with diazepam led to enhanced anxiolytic-like efficacy. Moreover, as with diazepam, the anxiolytic-like effect of the analog was reduced by flumazenil. In contrast, bicuculline, a GABAA antagonist, had no effect on the activity of the derivative. Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABAA-benzodiazepine receptor complex.

KW - Anxiolytic-like activity

KW - Elevated plus-maze

KW - Honokiol

KW - Honokiol analogs

KW - Hydrogenated honokiols

UR - http://www.scopus.com/inward/record.url?scp=0034490963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034490963&partnerID=8YFLogxK

U2 - 10.1016/S0091-3057(00)00401-9

DO - 10.1016/S0091-3057(00)00401-9

M3 - Article

C2 - 11164091

AN - SCOPUS:0034490963

VL - 67

SP - 597

EP - 601

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 3

ER -